Status: Ongoing
First registered on:
13/06/2015
Last updated on:
12/05/2016
1. Study identification
EU PAS Register NumberEUPAS9953
Official titleOne Year Post-discharge Clinical and Economic Outcomes among Patients with ACS Managed with PCI and Treated with Prasugrel versus Clopidogrel
Study title acronymH7T-MC-B022
Study typeObservational study
Brief description of the studyRetrospective cohort study using the Optum Research Claims Database to compare clinical and economic outcomes and treatment patterns among patients treated with prasugrel and those treated with clopidogrel. The primary study population will be patients with ACS managed with PCI who have no prior TIA or stroke (that is, the indicated population for treatment with prasugrel). Primary study objective is to compare major adverse cardiac events (MACE) up to one year and secondary endpoints will include clinical and economic outcomes and treatment patterns through 1 year post index hospitalisation discharge. Data will be assessed before and after adjustment for baseline risk differences via propensity score matching. The subgroup of the primary population aged <75years or >75 years with diabetes or prior MI, will also be assessed (that is, the population recommended for treatment with prasugrel per USPI).
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)?
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsOptum
Department/Research groupHealth Economics and Outcomes Research
Organisation/affiliationOptum
Details of (Primary) lead investigator
Title Dr
Last name Molife
First name Cliff
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
National study
United States
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed31/10/201331/10/2013
Start date of data collection01/03/201401/04/2014
Start date of data analysis01/05/201401/06/2014
Date of interim report, if expected01/09/2015
Date of final study report01/10/2015
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesEli Lilly and Company100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Dr
Last name Molife
First name Cliff
Address line 1Lilly Technology Center South
Address line 21555 S Harding St
Address line 3
CityIndianapolis
Postcode46221
CountryUnited States
Phone number (incl. country code)13172207074
Alternative phone number
Fax number (incl. country code)13172777444
Public Enquiries
Title Dr
Last name Molife
First name Cliff
Address line 1Lilly Technology Center South
Address line 21555 S Harding St
Address line 3
CityIndianapolis
Postcode46221
CountryUnited States
Phone number (incl. country code)13172207074
Alternative phone number
Fax number (incl. country code)13172777444
6. Study drug(s) information
Substance class (ATC Code)B01AC22 (prasugrel)
Substance class (ATC Code)B01AC04 (clopidogrel)
7. Medical conditions to be studied
Medical condition(s)Yes
Acute coronary syndrome
8. Population under study
Age
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects26079
Additional information
Prasugrel: n=5,289
Clopidogrel: n=20,790
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources not registered with ENCePP
Optum Research Database, United States
Sources of data
Administrative database, e.g. claims database
11. Scope of the study
What is the scope of the study?
Effectiveness evaluation
Primary scope : Effectiveness evaluation
12. Main objective(s)
What is the main objective of the study?
The primary study objective is to compare major adverse cardiovascular events (MACE) up to 1 year post-discharge from an index ACS-PCI hospitalization in patients treated with prasugrel versus clopidogrel. The main hypothesis is that, after adjustment for baseline differences, prasugrel will be associated with a significantly lower risk of MACE than clopidogrel up to one year post-discharge.
Are there primary outcomes?Yes
Major adverse cardiovascular events (MACE) up to 1 year post discharge from an index ACS-PCI hospitalization.
Are there secondary outcomes?Yes
Resource utilization (medical and pharmacy utilization) and other clinical outcomes (MACE components, bleeding rehospitalizations); healthcare charges; and treatment patterns (including adherence and persistence) at one year post discharge from the index hospitalization.
13. Study design
What is the design of the study?
Cohort study
14. Follow-up of patients
Will patients be followed up?Yes
Please describe duration of follow up
Duration of follow-up: Up to 1 year
15. Data analysis plan
Please provide a brief summary of the analysis method
Baseline and outcomes data will be analyzed before and after propensity matching. Treatment groups will be matched based on baseline demographic, clinical, procedural, and payer characteristics. Multivariable cox regression will be used to compare adjusted clinical outcomes. Unmatched cohorts will be compared with the appropriate 2-tailed statistic for continuous or categorical variables. Patients will be censored at the end of index treatment exposure time (that is, 7 days after discontinuation or switching of the index medication). Pre- and post-match Kaplan Meier curves will be constructed and log-rank tests used to compare unadjusted rates through 1 year. Per patient per month economic measures and incidence rates will be assessed to account for the variable follow-up period. Economic outcomes and treatment patterns will also be analyzed after matching using descriptive statistics and appropriate regression models (for example, generalized linear model and logistic regression).
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
Available when the study ends
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documents
DescriptionDocumentLatest version
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
